Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lithium cation
Drug ID BADD_D01304
Description Lithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression. Lithium can also be used to augment other antidepressant drugs. It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches. The active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several critical neuronal enzymes and neurotransmitter receptors.
Indications and Usage Lithium, in its salt forms, is used as a mood stabilizer and for the treatment of depression and mania. It is most frequently prescribed in the treatment of bipolar disorder.
Marketing Status experimental
ATC Code N05AN01
DrugBank ID DB01356
KEGG ID D08133
MeSH ID D008094
PubChem ID 28486
TTD Drug ID D5MF8Y
NDC Product Code Not Available
UNII 8H8Z5UER66
Synonyms Lithium | Lithium-7 | Lithium 7
Chemical Information
Molecular Formula Li+
CAS Registry Number 17341-24-1
SMILES [Li+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Injection site pain12.07.03.011; 08.02.03.0100.000979%Not Available
Injection site reaction08.02.03.014; 12.07.03.0150.001075%
Intention tremor17.01.06.0050.000288%Not Available
Intentional self-injury19.12.01.002; 12.01.08.0360.000288%Not Available
Intracranial pressure increased17.07.02.0020.000192%Not Available
Kidney fibrosis20.01.02.0110.000192%Not Available
Lethargy17.02.04.003; 08.01.01.008; 19.04.04.0040.001421%
Leukocytosis01.02.01.0020.001191%
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.005--Not Available
Loss of consciousness17.02.04.0040.001248%Not Available
Mania19.16.02.0020.001767%
Memory impairment19.20.01.003; 17.03.02.0030.000806%
Mental impairment19.21.02.003; 17.03.03.0020.000576%Not Available
Metabolic acidosis14.01.01.0030.001056%Not Available
Multiple sclerosis17.16.01.001; 10.04.10.0080.000192%Not Available
Muscle contractions involuntary17.05.03.001; 15.05.03.008--Not Available
Muscle rigidity15.05.04.001; 17.05.02.0050.000768%Not Available
Muscle twitching15.05.03.0050.000614%Not Available
Muscular weakness17.05.03.005; 15.05.06.0010.000710%
Myasthenia gravis15.05.08.001; 10.04.05.001; 17.05.04.001--
Myocarditis02.04.03.0010.000672%
Myoclonus17.02.05.0080.001728%Not Available
Myxoedema23.07.04.007; 05.02.03.002--Not Available
Nausea07.01.07.001--
Nephrogenic diabetes insipidus20.05.03.010; 14.05.07.0020.006471%Not Available
Nephropathy20.05.03.0010.003495%Not Available
Nephropathy toxic20.05.03.002; 12.03.01.0100.002016%Not Available
Nervous system disorder17.02.10.0010.000672%Not Available
Neuroleptic malignant syndrome17.05.02.003; 15.05.04.015; 12.03.01.003; 08.05.01.0050.000960%Not Available
Neurotoxicity17.02.10.002; 12.03.01.0110.001632%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 11 Pages